PRA is Named International Clinical Company of the Year

Food and Healthcare Press Releases Monday April 27, 2015 18:39
RALEIGH, N.C.--(GLOBE NEWSWIRE)--April 27, 2015

PRA Health Sciences (PRA) is pleased to announce that it was named Clinical Company of the Year at the International Clinical Researcher of the Year award ceremony in London. This is the second year in a row that PRA has won this prestigious award. PRA also swept the Clinical Team of the Year category. PRA winners include:

-- Clinical Research Associate: Charlotte Holmes
-- Project Manager: Silvia Casellas
-- Clinical Team Leader: Emma Lewis
-- Clinical Team: Sarah Gage, Ashley King, Katy Mercer, Jo Perry
PRA was also recognized with five Silver awards and one Bronze.

"PRA is delighted to receive these awards," said Sean Leech, Executive Vice President, PRA Health Sciences. "This recognition is a testament to the caliber and talent of all our dedicated employees and we are immensely proud of their accomplishments."

Organized by PharmaTimes, the International Clinical Researcher of the Year competition is considered a key barometer of quality standards in the clinical research industry. The competition is judged by independent clinical research experts and is designed to "recognize, encourage and inspire professionalism in tomorrow's leaders."

In the 2015 competition PRA competed against finalists from 22 pharmaceutical companies and clinical research organizations from around the world. The Clinical Researcher of the Year Americas award ceremony is scheduled for June 4, 2015 in Raleigh, North Carolina. PRA is well represented with 17 finalists.

ABOUT PRA HEALTH SCIENCES

PRA Health Sciences is one of the world's leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions(TM) model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.

CONTACT: MEDIA INQUIRIES:
Christine Rogers, Manager - Public Relations,
Corporate Communications
EMAIL: rogerschristine@prahs.com
PHONE: +1 919.786.8463
INVESTOR INQUIRIES:
InvestorRelations@prahs.com

Latest Press Release

Venus Medtech Launches Global Advisory Board to Target for International Market

Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board. The Board...

Future Health Index, Commissioned by Philips, Identifies Key Recommendations for Better Health Information Exchange to Drive Value in Healthcare

Royal Philips (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today released a new Future Health Index (FHI) report " Moving data to the heart of health systems: Increasing vital technology adoption to make value-based healthcare a reality...

PULSUS Group collaborates with Anbu Kochi to Contribute towards Kerala Flood Victims

In a humanitarian effort, PULSUS Group - in collaboration with Anbu Kochi - is responding to the calamity of the recent, unprecedented floods in the Indian state of Kerala by providing contributions to aid relief and rehabilitation measures. PULSUS Group...

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular...

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

Related Topics